Listed by the USPTO as NATARAJAN, MEERA
Tech Center 1600 • Art Units: 1643 1645 1646 1674
This examiner grants 63% of resolved cases
NATARAJAN, MEERA is a USPTO patent examiner in Tech Center 1600 and Art Unit 1643. The profile records 769 resolved cases, a 62.7% allowance rate, and a median of 1178 days to allowance. This volume gives practitioners a broad historical record for assessing prosecution posture and expected timing.
The interview lift is 17.8%, providing a basis for considering interviews alongside claim amendments and written responses. The listed companies are Santersus AG, Xencor Inc., and Hoffmann-La Roche Inc. The listed firms are MEDLER FERRO WOODHOUSE & MILLS PLLC, TROUTMAN PEPPER LOCKE LLP, and MARSHALL, GERSTEIN & BORUN LLP.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18627727 | COMBINED ADMINISTRATION | Non-Final OA | Hoffmann-La Roche Inc. |
| 18528157 | ANTI- GPRC5D ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND GPRC5D AND CD3, AND USES THEREOF | Non-Final OA | Janssen Biotech, Inc. |
| 17997482 | ENGINEERED IMMUNOGLOBULINS | Final Rejection | Novartis AG |
| 17969033 | METHODS FOR TREATING PRURIGO NODULARIS BY ADMINISTERING AN IL-4R ANTAGONIST | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 18224865 | GENERATION OF ANTI-TUMOR T CELLS | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 18338313 | NOVEL METHOD FOR PRODUCING ANTIBODIES | Non-Final OA | TSINGHUA UNIVERSITY |
| 18430415 | BISPECIFIC ANTIBODY CONSTRUCTS FOR CDH3 AND CD3 | Non-Final OA | AMGEN RESEARCH (MUNICH) GMBH |
| 18690886 | USE OF ANTI-CD40 ANTIBODY | Non-Final OA | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
| 18480038 | ANTIBODY FUSION PROTEIN AND RELATED COMPOSITIONS FOR TARGETING CANCER | Non-Final OA | Arizona Board of Regents on Behalf of Arizona State University |
| 18639592 | COMPOSITIONS AND METHODS FOR MODULATING HYDROXYLATION OF ACC2 BY PHD3 | Non-Final OA | President and Fellows of Harvard College |
| 18558882 | DOUBLE SIDED CHIMERIC ANTIGEN RECEPTOR (CAR) ENGINEERED CELL MEMBRANE BASED DRUG DELIVERY SYSTEMS | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18705759 | COMPOSITIONS FOR CELL-BASED THERAPIES AND RELATED METHODS | Non-Final OA | SIGILON THERAPEUTICS, INC. |
| 18290668 | NOVEL CHIMERIC ANTIGEN RECEPTOR AND IMMUNE CELLS EXPRESSING SAME | Non-Final OA | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy62.7% of resolved applications examined by Meera Natarajan were allowed (769 resolved cases), compared with 41.5% across Art Unit 1643 over the last five years.
This examiner's interview lift is +17.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Meera Natarajan took 1,178 days on average from filing to allowance.
Meera Natarajan examines applications in Art Unit 1643 in Tech Center 1600 (Biotechnology & Pharmaceuticals).